Interleukin-1 receptor antagonist in head and neck squamous cell carcinoma
- PMID: 8663949
- DOI: 10.1001/archotol.1996.01890190047012
Interleukin-1 receptor antagonist in head and neck squamous cell carcinoma
Abstract
Background: We hypothesized that in head and neck squamous cell carcinoma, the overexpression of protumorigenic interleukin-1 (IL-1) activity within the tumor tissue is a result of decreased expression of the specific antagonist or inhibitor (ie, IL-1 receptor antagonist) by the tumor cells. Ultimately, this local overexpression of IL-1 activity increases tumor growth and metastasis.
Design: To test our hypotheses, immunologic analysis for IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist was performed on histologic sections and tumor homogenates of human head and neck squamous cell carcinomas.
Setting: University teaching hospital.
Patients or other participants: Normal and tumor specimens were obtained from patients undergoing surgical resections of the head and neck for benign and malignant disease.
Results: Immunohistochemical analysis demonstrated the presence of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist within tumor cells and inflammatory cells in the tumor stroma in 19 of 19 tumor specimens. Quantitatively, IL-1 alpha was present in 19 of 19 tumor specimens (1.97 +/- 0.46 ng/mg of total protein [mean +/- SD]) and 5 of 9 normal specimens (0.23 +/- 0.12 ng/mg of total protein). All specimens contained IL-1 beta in detectable quantities (1.60 +/- 0.29 ng/mg of total protein in tumor specimens and 0.189 +/- 0.04 ng/mg of total protein in normal specimens). All specimens contained IL-1 receptor antagonist (368.87 +/- 57.63 ng/mg of total protein in tumor specimens and 585.10 +/- 166.03 ng/mg of total protein in normal specimens). The mean total IL-1/IL-1 receptor antagonist ratio was 13.26 +/- 2.31 in patients with cancer compared with 0.997 +/- 0.26 in normal patients.
Conclusions: The increased IL-1 index in the cancer state compared with the normal state reflects an imbalance of IL-1 and IL-1 receptor antagonist, which may contribute to unrestricted growth and metastasis of head and neck squamous cell carcinoma.
Similar articles
-
Phospholipid metabolite expression by head and neck squamous cell carcinoma.Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):763-9. doi: 10.1001/archotol.1994.01880310065012. Arch Otolaryngol Head Neck Surg. 1994. PMID: 8018329
-
Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma.Laryngoscope. 1999 May;109(5):687-93. doi: 10.1097/00005537-199905000-00002. Laryngoscope. 1999. PMID: 10334214
-
Interleukin-8 expression by head and neck squamous cell carcinoma.Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):202-9. doi: 10.1001/archotol.1995.01890020064013. Arch Otolaryngol Head Neck Surg. 1995. PMID: 7840929
-
Immunohistochemical studies in the identification of lymph node micrometastases in patients with squamous cell carcinoma of the head and neck.ORL J Otorhinolaryngol Relat Spec. 2004;66(1):38-41. doi: 10.1159/000077232. ORL J Otorhinolaryngol Relat Spec. 2004. PMID: 15103200 Review.
-
The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies.Dan Med Bull. 1998 Apr;45(2):121-34. Dan Med Bull. 1998. PMID: 9587699 Review.
Cited by
-
Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas.Heliyon. 2023 Mar 28;9(4):e14960. doi: 10.1016/j.heliyon.2023.e14960. eCollection 2023 Apr. Heliyon. 2023. PMID: 37025835 Free PMC article. Review.
-
Inflammatory Mediators in Oral Cancer: Pathogenic Mechanisms and Diagnostic Potential.Front Oral Health. 2021 Feb 22;2:642238. doi: 10.3389/froh.2021.642238. eCollection 2021. Front Oral Health. 2021. PMID: 35047997 Free PMC article. Review.
-
IL1RA inhibits the progression of oral squamous cell carcinoma by mediating type Ⅰ interferon response.Transl Oncol. 2025 Aug;58:102428. doi: 10.1016/j.tranon.2025.102428. Epub 2025 May 28. Transl Oncol. 2025. PMID: 40441062 Free PMC article.
-
Importance of interleukin-1 and interleukin-1 receptor antagonist in short-term glucose sensor function in vivo.J Diabetes Sci Technol. 2010 Sep 1;4(5):1073-86. doi: 10.1177/193229681000400506. J Diabetes Sci Technol. 2010. PMID: 20920427 Free PMC article.
-
Effects of in IL-1B/IL-1RN variants on the susceptibility to head and neck cancer in a chinese Han population.Cancer Cell Int. 2021 Jan 20;21(1):59. doi: 10.1186/s12935-021-01750-0. Cancer Cell Int. 2021. PMID: 33472637 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical